Breaking News

NHTSA Had ‘Ample Information’ to Find GM Ignition Switch Defect: Report
Tweet TWEET

Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call

  Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call

Business Wire

ROCKVILLE, Md. -- February 25, 2014

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical
company focused on developing and commercializing products for the treatment
of central nervous system diseases, today announced that the Company expects
to report fourth quarter and full year 2013 financial results after the market
closes Wednesday, March 12, 2014. CEO, Jack Khattar, and CFO, Greg Patrick,
will be hosting a conference call on Thursday, March 13, 2014 at 9:00 AM
Eastern Time, to discuss 2013 financial results and to provide a business
update.

A live webcast will be available at www.supernus.com. Following the live call,
a replay will be available on the Company's website under ’Investor Info’. The
webcast will be archived on the Company's website for 30 business days
following the live call.

Please refer to the information below for conference call dial-in information.
Callers should dial in approximately 10 minutes prior to the start of the
call.

                        
Conference dial-in:        877-288-1043
International dial-in:     970-315-0267
Conference ID:             54977145
Conference Call Name:      Supernus Pharmaceuticals 4Q 2013 Earnings
                           Conference Call
                           

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has two marketed products for
epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™
(extended-release topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in ADHD,
including ADHD patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Contact:

Supernus Pharmaceuticals, Inc.
Jack A. Khattar, 301-838-2591
President and CEO
or
Gregory S. Patrick, 301-838-2591
Vice President and CFO
or
Investor Contact:
Cockrell Group, 877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
 
Press spacebar to pause and continue. Press esc to stop.